Academic Cancer Center Phase I Program Development

This commentary assesses the factors necessary for the effectiveness of academic phase I cancer programs. The metrics presented here may be useful as a rubric for new and established programs.

[1]  D. Sullivan,et al.  Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials , 2015, American journal of clinical oncology.

[2]  Laura A. Levit,et al.  Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Fouad,et al.  Patient Navigation As a Model to Increase Participation of African Americans in Cancer Clinical Trials. , 2016, Journal of oncology practice.

[4]  J. Soria,et al.  A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials , 2016, PloS one.

[5]  E. Traut-Mattausch,et al.  Comparing the Effectiveness of Individual Coaching, Self-Coaching, and Group Training: How Leadership Makes the Difference , 2016, Front. Psychol..

[6]  T. Yankeelov,et al.  Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  Lei Wang,et al.  Employee Trust in Supervisors and Affective Commitment , 2016, Psychological reports.

[8]  M. Gönen,et al.  Assessing Clinical Trial-Associated Workload in Community-Based Research Programs Using the ASCO Clinical Trial Workload Assessment Tool. , 2016, Journal of oncology practice.

[9]  Amber Jessup,et al.  Key cost drivers of pharmaceutical clinical trials in the United States , 2016, Clinical trials.

[10]  Andrei I Holodny,et al.  Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. , 2016, Neuro-oncology.

[11]  J. Berlin,et al.  A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[12]  D. Mahalingam,et al.  Advanced Cancer Patients’ Understanding and Perceptions of Phase I Clinical Trials , 2015, Cancer investigation.

[13]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[14]  Xian-Jin Xie,et al.  Impact of NCI-mandated scientific review on protocol development and content. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[15]  A. Wang-Gillam,et al.  Paving the road to clinical trial participation: removing road blocks and directing patients toward novel therapies. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[16]  S. Weitman,et al.  Eligibility of patients with renal impairment for Phase I trials: Time for a rethink? , 2014, European journal of cancer.

[17]  B. Pollock,et al.  Promoting Factors and Barriers to Participation in Early Phase Clinical Trials: Patients Perspectives. , 2014, Journal of community medicine & health education.

[18]  K. Hess,et al.  The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  J. Michalek,et al.  An evaluation of elderly patients (≥70 years old) enrolled in Phase I clinical trials at University of Texas Health Science Center at San Antonio-Cancer Therapy Research Center from 2009 to 2011. , 2014, Journal of geriatric oncology.

[20]  W. McCaskill-Stevens,et al.  The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. , 2013, Journal of oncology practice.

[21]  I. Thompson,et al.  The Development of a Minority Recruitment Plan for Cancer Clinical Trials. , 2013, Journal of community medicine & health education.

[22]  Amy P Abernethy,et al.  Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. , 2013, JAMA internal medicine.

[23]  D. Planchard,et al.  Clinical Benefit for Patients with Non-Small Cell Lung Cancer Enrolled in Phase I Trials , 2013, Oncology Research and Treatment.

[24]  L. Siminoff,et al.  Barriers to therapeutic clinical trials enrollment: Differences between African-American and white cancer patients identified at the time of eligibility assessment , 2012, Clinical trials.

[25]  B. Pollock,et al.  Early Phase Clinical Trials: Referral Barriers and Promoters among Physicians. , 2012, Journal of community medicine & health education.

[26]  Razelle Kurzrock,et al.  Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative , 2012, Clinical Cancer Research.

[27]  R. Kurzrock,et al.  Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience , 2012, Clinical Cancer Research.

[28]  R. Kurzrock,et al.  Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center , 2012, Cancer.

[29]  Brian J. Smith,et al.  Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia , 2012, Leukemia and Lymphoma.

[30]  D. V. Von Hoff,et al.  Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials , 2011, Journal of Cancer.

[31]  D. Dilts,et al.  A Sense of Urgency: Evaluating the Link between Clinical Trial Development Time and the Accrual Performance of Cancer Therapy Evaluation Program (NCI-CTEP) Sponsored Studies , 2010, Clinical Cancer Research.

[32]  F. Gao,et al.  Time to activate lung cancer clinical trials and patient enrollment: a representative comparison study between two academic centers across the atlantic. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  R. Schilsky,et al.  American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  N. Petrelli,et al.  Clinical trial investigator status: you need to earn it. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Ledermann.  Phase I Cancer Clinical Trials , 2007, British Journal of Cancer.

[36]  David M Dilts,et al.  Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Buyse,et al.  Phase I Cancer Clinical Trials: A Practical Guide , 2006 .

[38]  C. Tangen,et al.  Guidelines for data and safety monitoring for clinical trials not requiring traditional data monitoring committees , 2006, Clinical trials.

[39]  L. Fallowfield,et al.  Communication and informed consent in phase 1 trials: a review of the literature , 2006, Supportive Care in Cancer.

[40]  R. Dierckx,et al.  Good clinical practice: historical background and key aspects. , 2005, Nuclear medicine communications.

[41]  B. Chabner,et al.  Chemotherapy and the war on cancer , 2005, Nature Reviews Cancer.

[42]  D. Weiner,et al.  Monitoring Participant Safety in Phase I and II Interventional Trials: Options and Controversies , 2004, Journal of Investigative Medicine.

[43]  M. Terrin.  Evaluating and Implementing Data and Safety Monitoring Plans , 2004, Journal of Investigative Medicine.

[44]  D. DeMets,et al.  Issues in regulatory guidelines for data monitoring committees , 2004, Clinical trials.

[45]  L. Wilhelmsen.  Role of the Data and Safety Monitoring Committee (DSMC) , 2002, Statistics in medicine.